Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This case report highlights a successful treatment with granulocyte colony-stimulating factor for cyclic neutropenia in a 16-year-old girl experiencing recurring oral aphthae and fever.

This study found that CDK4/6 inhibitors for HR+/HER2- advanced breast cancer are linked to typical adverse events such as fatigue and neutropenia, while also identifying unexpected reactions, highlighting potential safety concerns in their real-world use.

The conclusion is that different blood diseases cause specific oral symptoms and require varied treatments to manage these symptoms and improve patient health.

This review discusses the oral manifestations associated with hematologic conditions and nutritional deficiencies, without presenting new research results; it emphasizes the impact of blood disorders and vitamin deficiencies on oral health.

This review discusses the use of CDK4/6 inhibitors with endocrine therapy in treating women with HR+ HER2- advanced breast cancer, but it reports no new clinical findings.

In this multicentric retrospective study, researchers reported that cutaneous adverse events were common among advanced breast cancer patients treated with cyclin-dependent kinase inhibitors (CDK4/6i), generally mild, and manageable with topical treatments, though in some cases, they led to treatment discontinuation.

This study conducted in an Iraqi oncology setting found generic Palbociclib to have a safety profile consistent with previous data, with observed side effects including high rates of neutropenia and anemia, particularly among patients receiving it with Fulvestrant.

In this study, albendazole treatment in patients with hydatid disease was associated with decreased microsomal enzyme function and induced its own metabolism, but also showed potential hepatotoxicity and severe side effects, necessitating careful monitoring.

This review discusses various strategies to mitigate taxane-induced alopecia in cancer treatment, highlighting the potential of low-intensity ultrasound to reverse hair follicle damage by disrupting taxane-stabilized microtubules.

In this study, the researchers found that different CDK4/6 inhibitors used in treating HR+/HER2- advanced breast cancer have varying safety profiles and impacts on patient quality of life.

In this study, researchers presented cases of cellular neurothekeoma in three male family members with early-onset in infancy, suggesting a potential genetic component and inheritance pattern, which deviates from the typical presentation seen mostly in women between 20–30 years.

This study reports that Asparagus racemosus and Withania somnifera extracts significantly reduced paclitaxel-induced myelosuppression and morbidity in mice, suggesting their potential as therapeutic adjuvants in cancer management.

This phase II trial found that BI 2536 demonstrated limited antitumor activity across five solid tumor types, with no confirmed objective responses observed.

This clinical study observed that in patients with advanced breast cancer and BRCA1/2 mutations, talazoparib provided significantly better progression-free survival, objective response, clinical benefit, and patient-reported outcomes compared to physician’s choice chemotherapy, despite common side effects like anemia and fatigue.

In this study, researchers used a murine model of irritant contact dermatitis to reveal that hair follicle regions serve as key sites for neutrophil transepidermal migration, which requires MMP-9 expression stimulated by dermal monocytes.

This study found that 49% of female breast cancer patients treated with CDK4/6 inhibitors for at least three months developed alopecia, which significantly impacted their quality of life, with greater alopecia severity leading to worse emotional and functional well-being.

This report details a case of hair, nail, and pigmentary disorders occurring 10 months after starting abemaciclib for metastatic breast cancer, highlighting that cutaneous side effects, although less frequent, can lead to discontinuation in 25% of cases.

This article reviews the potential for low intensity ultrasound as an antidote for the peripheral cytotoxic side effects of taxane drugs in chemotherapy, presenting no new clinical results.

Docetaxel, a chemotherapy drug, was reported to cause psoriasis in a patient for the first time.

This study found that TLR2 expression in hair follicle stem cells is crucial for hair follicle maintenance and regeneration, with TLR2-dependent activation potentially offering new therapeutic approaches for hair loss prevention through mechanisms involving immune pathways and CEP administration.

This review discusses the use of recombinant cytokines as therapeutic agents in clinical settings and describes the range of cutaneous complications associated with their use, including both minor and severe skin reactions.

In this study, skin manifestations were observed in 48% of children with primary immunodeficiency disorders, often providing crucial diagnostic clues for early identification of these conditions.

This study found that dietary yeast cell wall supplementation in broiler chickens increased certain immune responses compared to antibiotic treatments following immunization with sheep red blood cells.

This case report highlights the successful use of platelet-rich plasma infiltration to treat vasopressin-induced bilateral foot digit gangrene in a 20-year-old female, suggesting its potential in stimulating angiogenesis and wound healing, though further research is necessary to assess its general efficacy.

This review discusses the various evidence-based and potential applications of metformin in treating and preventing symptoms and complications associated with polycystic ovary syndrome but reports no new clinical results.

This review elaborates on the skin side effects of chemotherapy and emphasizes identifying and managing both common and life-threatening skin reactions, without presenting new clinical findings.

This review discusses current treatment options for liver hydatidosis, noting the potential benefits and limitations of chemotherapy and highlighting the need for more clinical trials to prevent recurrent disease; it reports no new findings.

This review discusses the historical development, mechanisms of action, and potential new clinical applications of the drug cepharanthine, highlighting its multi-faceted pharmacological properties; it reports no new clinical results.

In this study, tofacitinib treatment was associated with significant hair regrowth in two patients with alopecia universalis over eight months, with minimal adverse effects reported.

This review discusses the role of pharmacological sciences in advancing regenerative medicine technologies but reports no new experimental findings; the authors advocate for increased pharmacologist involvement to drive innovations.